Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study

被引：0

作者：

Engert, A. ^{[1
]}

Domingo Domenech, E. ^{[2
]}

Rueda, A. ^{[3
]}

Armand, P. ^{[4
]}

Trneny, M. ^{[5
]}

Feldman, T. ^{[6
]}

Ansell, S. ^{[7
]}

Provencio, M. ^{[8
]}

Jaeger, U. ^{[9
]}

Cohen, J. B. ^{[10
]}

Savage, K. J. ^{[11
]}

Willenbacher, W. ^{[12
,13
]}

Sacchi, M. ^{[14
]}

Sumbul, A. ^{[14
]}

Ramchandren, R. ^{[15
]}

机构：

[1] Univ Hosp Cologne, Cologne, Germany

[2] ICO, Barcelona, Spain

[3] Costa del Sol Hosp, Marbella, Spain

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] Mayo Clin, Rochester, MN USA

[8] Hosp Univ Puerta de Hierro, Madrid, Spain

[9] Med Univ Vienna, Vienna, Austria

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Canc Agcy Ctr Lymphoid Canc, Vancouver, BC, Canada

[12] Univ Innsbruck Hosp, Innsbruck, Austria

[13] OncoTyrol Ctr Personalized Care Med, Innsbruck, Austria

[14] Bristol Myers Squibb, Princeton, NJ USA

[15] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V853

引用

页码：273 / 273

页数：1

共 50 条

[1] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Rueda, Antonio
Armand, Philippe
Trneny, Marek
Feldman, Tatyana A.
Ansell, Stephen M.
Provencio, Mariano
Jaeger, Ulrich
Cohen, Jonathon B.
Savage, Kerry J.
Willenbacher, Wolfgang
Sacchi, Mariana
Sumbul, Anne
Domenech, Eva Domingo
BLOOD, 2017, 130
[2] Nivolumab plus Doxorubicin, Vinblastine and Dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2-year follow-up results
Engert, A.
Domingo-Domenech, E.
Ramchandren, R.
Rueda, A.
Trneny, M.
Feldman, T.
Lee, H. J.
Provencio, M.
Sillaber, C.
Cohen, J. B.
Savage, K. J.
Willenbacher, W.
Sumbul, A.
Sacchi, M.
Armand, P.
Ansell, S. M.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 162 - 162
[3] NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR FOLLOW-UP IN THE CHECKMATE 205 STUDY
Domingo-Domenech, E.
Ramchandren, R.
Rueda, A.
Trne
Ny, M.
Feldman, T.
Hun, Lee J.
Provencio, M.
Sillaber, C.
Cohen, J. B.
Savage, K. J.
Willenbacher, W.
Sumbul, A.
Sacchi, M.
Armand, P.
Ansell, S.
HAEMATOLOGICA, 2019, 104 : 21 - 22
[4] Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Ramchandren, Radhakrishnan
Domingo-Domenech, Eva
Rueda, Antonio
Trneny, Marek
Feldman, Tatyana A.
Lee, Hun Ju
Provencio, Mariano
Sillaber, Christian
Cohen, Jonathon B.
Savage, Kerry J.
Willenbacher, Wolfgang
Ligon, Azra H.
Ouyang, Jing
Redd, Robert
Rodig, Scott J.
Shipp, Margaret A.
Sacchi, Mariana
Sumbul, Anne
Armand, Philippe
Ansell, Stephen M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) : 1997 - +
[5] Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A plus AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)
Franklin, Anna
Zecca, Marco
Fagioli, Franca
Luisi, Flavio Augusto
Song, Gregory
Suri, Ajit
Leonard, E. Jane
Locatelli, Franco
BLOOD, 2018, 132
[6] Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL).
Keating Franklin, Anna Rachel
Luisi, Flavio
Pianovski, Mara
Salvino, Marco Aurelio
Fagioli, Franca
Epelman, Sidnei
Lima, Luciana
Norris, Robin Elizabeth
Odone-Filho, Vicente
Zecca, Marco
Favre, Claudio
Kobayashi, Ryoji
Koga, Yuhki
Sidi, Yulia
Zhou, Xiaofei
Bai, Xiang
Campana, Frank
Leonard, E. Jane
Locatelli, Franco
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress).
Friedman, Judah D.
Lee, Hun Ju
Ho, Linda
Flinn, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
Armand, Philippe
Shipp, Margaret Ann
Kuruvilla, John
Collins, Graham P.
Ramchandren, Rod
Timmerman, John
Sumbul, Anne
Ruisi, Mary M.
Kato, Kazunobu
Ansell, Stephen Maxted
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A plus AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
Younes, Anas
Radford, John
Ansell, Stephen Maxted
Gallamini, Andrea
Kim, Wom Seog
Feldman, Tatyana A.
Hamadani, Mehdi
Chung, Jeanenne
Wang, Jingyuan
Huebner, Dirk
Connors, Joseph M.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Herrera, Alex F.
Li, Hongli
Castellino, Sharon M.
Rutherford, Sarah C.
Davison, Kelly
Evans, Andrew G.
Punnett, Angela
Constine, Louis S.
Hodgson, David C.
Parsons, Susan K.
Prica, Anca
Kostakoglu, Lale
Shipp, Margaret A.
Laubach, Cara
Leblanc, Michael L.
Crump, Michael
Kahl, Brad S.
Leonard, John P.
Kelly, Kara M.
Smith, Sonali M.
Friedberg, Jonathan W.
BLOOD, 2020, 136

← 1 2 3 4 5 →